Senior Medical Director, Rare Metabolics, US Medical Affairs

AstraZeneca•Boston, MA

7d•Hybrid

About The Position

Are you ready to lead US medical strategy in rare metabolics and translate sophisticated biology into tangible impact for people living with HPP and LAL-D? In this role, you will set direction, accelerate evidence generation, and elevate scientific exchange to advance care in conditions with significant unmet need. Your leadership will shape how we engage with clinicians, researchers, and key institutions to improve patient journeys and outcomes. You will guide an evolving US medical team, harmonize efforts with global colleagues, and ensure our scientific communications and medical education drive clarity and action. Imagine building a high-performing US Medical Affairs capability where insights from advisory boards, congresses, and field teams inform strategy week to week—how will you connect those dots to sharpen our plans? Accountabilities: Medical Strategy Leadership: Define and deliver the US medical strategy and in-year tactical plan for rare metabolics, aligning with global teams and the TA Lead to set clear priorities and field focus. Patient Journey and Product Strategy: Lead situational assessments of the patient journey and drive US product strategy, harmonizing KOL engagement with global medical affairs across HPP and LAL-D. Evidence Generation: Lead and collaborate on evidence generation projects, ensuring outputs inform clinical decision-making, registration programs, and lifecycle management. Scientific Communication and Education: Provide strategic guidance on scientific communications, internal medical training, CME and symposia, medical education, and medical information to ensure consistency and impact. KOL and Academic Partnerships: Establish strategic partnerships with KOLs and key academic institutions; work closely with field medical leadership to design and implement a targeted US KOL engagement strategy. Advisory Boards and Insights: Plan, design, and manage medical advisory boards; synthesize insights from boards, field interactions, and conferences into actionable updates to US medical plans. Registration Programs and LCM: Contribute medical acumen to registration programs with GMA and provide strategic recommendations for in-line LCM and potential pipeline assets. Investigator Sponsored Research: Provide medical review and ensure alignment of ISR proposals with HPP/LAL-D strategy throughout the asset lifecycle. Congress Representation: Represent US medical leadership at relevant US congresses, elevating our scientific presence and building credibility with collaborators. Commercial Collaboration: Offer medical perspective to commercial strategy, ensuring scientific integrity and patient-centric value in cross-functional plans. Budget and Resource Management: Develop, implement, and manage the budget plan for US rare metabolics medical initiatives, optimizing resources for high-impact delivery. Team Support and Leadership: Provide oversight and guidance to US Medical Directors or Associate Medical Directors; support the TA Lead on team performance and delivery of medical plans. Medical Expertise: Serve as the medical expert and resource for the therapeutic area within the US organization, enabling swift, evidence-based decisions. Essential Skills/Experience: Developing and implementing US strategy and plan for US MA activities for disease areas and therapeutics in rare metabolics franchise by providing medical leadership, insight and strategy to the evolving US HPP/LAL-D medical team across various internal functions. Providing, oversight and guidance to other current and/or future US Medical Directors or Associate Medical Directors in “dotted line” fashion Leading the situational assessment of the patient journey and the US product strategy development including harmonization of activities involving KOLs building from, and aligned with global medical affairs HPP/LAL-D teams and personnel Developing in-year and future medical strategy and tactical plan for the US Medical Affairs team working closely with the TA Lead, including key contributions to field focus Development, implementation and management of budget plan for US rare metabolics Medical Team initiatives. Providing strategic medical recommendations for in-line life cycle management (LCM) and potential pipeline assets Leading and collaborating on evidence generation projects Contributing with scientific and medical skill to registration programs working closely with GMA Providing medical review and ensuring alignment with HPP/LAL-D strategy of Investigator sponsored research (ISR) proposals at proper consideration times in lifecycle Providing clear strategic guidance about scientific communication, internal medical training, external medical education (CME, Symposia, medical education), Medical information. Contributing medical perspective to commercial strategy as appropriate Support TA lead with team’s performance in terms of goals and delivery of US medical plans Serving as the medical expert and resource within ALXN US in support of the therapeutic area. Leading content development and presentation for external medical education programs and other medical initiatives as appropriate Developing, conducting, or contributing to therapeutic training programs for Alexion personnel in conjunction with GMA training and Med Comm Leads Working closely with the Field team Directors in the development and execution of US KOL medical engagement strategy

Requirements

Developing and implementing US strategy and plan for US MA activities for disease areas and therapeutics in rare metabolics franchise by providing medical leadership, insight and strategy to the evolving US HPP/LAL-D medical team across various internal functions.
Providing, oversight and guidance to other current and/or future US Medical Directors or Associate Medical Directors in “dotted line” fashion
Leading the situational assessment of the patient journey and the US product strategy development including harmonization of activities involving KOLs building from, and aligned with global medical affairs HPP/LAL-D teams and personnel
Developing in-year and future medical strategy and tactical plan for the US Medical Affairs team working closely with the TA Lead, including key contributions to field focus
Development, implementation and management of budget plan for US rare metabolics Medical Team initiatives.
Providing strategic medical recommendations for in-line life cycle management (LCM) and potential pipeline assets
Leading and collaborating on evidence generation projects
Contributing with scientific and medical skill to registration programs working closely with GMA
Providing medical review and ensuring alignment with HPP/LAL-D strategy of Investigator sponsored research (ISR) proposals at proper consideration times in lifecycle
Providing clear strategic guidance about scientific communication, internal medical training, external medical education (CME, Symposia, medical education), Medical information.
Contributing medical perspective to commercial strategy as appropriate
Support TA lead with team’s performance in terms of goals and delivery of US medical plans
Serving as the medical expert and resource within ALXN US in support of the therapeutic area.
Leading content development and presentation for external medical education programs and other medical initiatives as appropriate
Developing, conducting, or contributing to therapeutic training programs for Alexion personnel in conjunction with GMA training and Med Comm Leads
Working closely with the Field team Directors in the development and execution of US KOL medical engagement strategy
Advanced degree (MD, PhD, PharmD) required
10+ years in Medical Affairs with significant leadership experience in rare diseases, metabolic disorders, or related therapeutic areas
Track record of designing and implementing US medical strategy, evidence generation plans, and KOL engagement at national scale
Deep understanding of HPP and LAL-D clinical landscape, diagnostic pathways, and treatment paradigms
Experience contributing to registration programs, lifecycle management, and ISR governance in alignment with global medical strategies
Proven success shaping scientific communications, CME and symposia content, and internal medical training for field teams
Strong cross-functional collaboration skills with commercial, HEOR, regulatory, and compliance partners
Demonstrated ability to manage budgets and resources while delivering high-impact medical initiatives
Established relationships with leading academic centers and medical societies; experience representing medical leadership at major congresses

Responsibilities

Medical Strategy Leadership: Define and deliver the US medical strategy and in-year tactical plan for rare metabolics, aligning with global teams and the TA Lead to set clear priorities and field focus.
Patient Journey and Product Strategy: Lead situational assessments of the patient journey and drive US product strategy, harmonizing KOL engagement with global medical affairs across HPP and LAL-D.
Evidence Generation: Lead and collaborate on evidence generation projects, ensuring outputs inform clinical decision-making, registration programs, and lifecycle management.
Scientific Communication and Education: Provide strategic guidance on scientific communications, internal medical training, CME and symposia, medical education, and medical information to ensure consistency and impact.
KOL and Academic Partnerships: Establish strategic partnerships with KOLs and key academic institutions; work closely with field medical leadership to design and implement a targeted US KOL engagement strategy.
Advisory Boards and Insights: Plan, design, and manage medical advisory boards; synthesize insights from boards, field interactions, and conferences into actionable updates to US medical plans.
Registration Programs and LCM: Contribute medical acumen to registration programs with GMA and provide strategic recommendations for in-line LCM and potential pipeline assets.
Investigator Sponsored Research: Provide medical review and ensure alignment of ISR proposals with HPP/LAL-D strategy throughout the asset lifecycle.
Congress Representation: Represent US medical leadership at relevant US congresses, elevating our scientific presence and building credibility with collaborators.
Commercial Collaboration: Offer medical perspective to commercial strategy, ensuring scientific integrity and patient-centric value in cross-functional plans.
Budget and Resource Management: Develop, implement, and manage the budget plan for US rare metabolics medical initiatives, optimizing resources for high-impact delivery.
Team Support and Leadership: Provide oversight and guidance to US Medical Directors or Associate Medical Directors; support the TA Lead on team performance and delivery of medical plans.
Medical Expertise: Serve as the medical expert and resource for the therapeutic area within the US organization, enabling swift, evidence-based decisions.